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RESULTS: Compared to the combined control groups, sig-
nificant long-term benefit attributable to the occupational
therapy intervention was found for six of the eight SF-36
domain scores: body pain, role functioning, vitality, social
functioning, role emotional, general mental health (p 
0.05). When we compared the occupational therapy group
with the combined control group, the incremental cost-
effectiveness ratio was $17,476 per QALY. Sensitivity anal-
yses confirmed that these quantitative results were robust.
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CONTROLLING FOR SIMULTANEITY BIAS IN 
OUTCOME STUDIES USING PANEL DATA
Luo R, Hay J, Hsiao C
The University of Southern California, Los Angeles, CA, USA
In outcome studies, healthcare costs and health status are
two focuses of primary interest. These two variables in-
teract with each other: change in health status results in
healthcare utilization and healthcare utilization has impact
on health status. This interaction necessitates a statistical
simultaneous modeling. Ignoring such endogeneity could
lead to inappropriate conclusions. Often, outcomes data
from clinical trials consist of panel data in which out-
comes are repeatedly measured over time. The nature of
panel data complicates statistical modeling to control for
this endogeneity bias.
OBJECTIVE: To present a statistical model and an esti-
mation procedure that are most suitable to tackling the
endogeneity between healthcare costs and health status
by using panel data from clinical trials.
METHOD: A simultaneous error-component model is
established as:
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where
The dependent variable and are the health expenditure and
health status of individual i (i  1, 2,. . ., N) at time t (t 
1,. . ., T); Xit is the vector of the common exogenous vari-
ables in both the cost and health equations; z1it is the vec-
tor of explanatory variables included in the cost equation
but not the health equation; z2it is the vector of explana-
tory variables included in the health equation but not the
cost equation.  are the unknown parameters; v1it and v2it
and are the unobserved disturbances which consist of 
i,
the component from an individual unit, t, the component
from a time period, uit, the independently identically dis-
tributed random disturbance. Given the structure of the
disturbances in the model, we propose the error-compo-
cit hitβ11 Xitβ12 zlitβ13 vlit+++=
hit citβ21 Xitβ22 z2itβ23 v2it+ + +=
v1it α1i λ1t u1it+ +=
v2it α2i λ2t u2it+ +=
nent three-stage least-squares method to estimate this
model.
IMPLICATION: This paper provides an example of
modeling costs and health status simultaneously using
panel data from clinical trials.
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COSTS OF HEALTHCARE FOR 8 YEARS PRIOR 
TO RECOGNITION OF TYPE 2 DIABETES (DM2)
Nichols GA, Brown JB
Center for Health Research, Portland, OR, USA
Type 2 Diabetes and its complications lead to higher
medical care costs, beginning at diagnosis and continuing
throughout life. But little is known about healthcare ex-
penditures and utilization prior to recognition of DM2.
We identified all members of Kaiser Permanente North-
west Region, a nonprofit HMO, diagnosed with DM2 in
1988 through 1995, and matched each of them to an
HMO member without DM based on age, gender, and
eligibility. We then observed outpatient, pharmaceutical,
and inpatient costs in the 8 years prior to diagnosis and
calculated incremental costs as the difference between
DM2s and their matched controls. Total costs for DM2s
and their matched controls were relatively flat 4 to 8 years
prior to diagnosis of DM2; incremental costs were not sig-
nificantly different from zero in those years. In the 3 years
immediately before diagnosis, however, DM2 costs rose
while control costs remained flat. By this measure, DM2
appears to cause significant excess total costs, starting
about 3 years prior to diagnosis. Considered on their own,
though, outpatient and pharmacy costs each exceeded
control costs during all 8 pre-diagnostic years. The major-
ity of incremental costs were for outpatient visits (62%).
We conclude that DM2 begins causing greater health ex-
penditures at least 8 years before diagnosis.
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PATIENTS ENROLLED IN MANAGED CARE 
ORGANIZATIONS
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Per-person medical costs by year prior to diagnosis of DM2
No. of
cases
Pre-DX
year
DM2
costs ($)
Control
costs ($)
Incremental
costs ($)
Percent
incremental (%)
708 	8 1774 1712 62 3%
1493 	7 2144 1767 377 18%
2397 	6 1872 1792 80 4%
3323 	5 2208 2005 203 9%
4269 	4 2238 2044 194 9%
5327 	3 2474 1911 563 23%
6490 	2 2536 1978 558 22%
8685 	1 2819 1949 870 31%
